EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 212 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible... November 18, 2024 Young Woman’s Breast Cancer Diagnosis Ends Up Saving Her Mom’s Life... September 27, 2021 How Alcohol Increases Your Cancer Risk and What to Know About... August 29, 2023 Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily... September 16, 2021 Load more HOT NEWS Despite Proven Safety of HPV Vaccines, More Parents Have Concerns This 11-Year-Old Is Starting College Next Year With A Plan To... Common Questions About COVID-19 and Cancer: Answers for Patients and Survivors Research with Integrity – integrating training into research culture
